Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold [Seeking Alpha]
Astria Therapeutics, Inc. (ATXS)
Company Research
Source: Seeking Alpha
The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Milko/iStock via Getty Images Astria Therapeutics: upgrading target price at $13, maintaining hold due to limited upside On the back of Biocryst Pharmaceutical ( BCRX ) announcing the acquisition of Astria Therapeutics ( ATXS ), I am updating the target This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of PHVS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am
Show less
Read more
Impact Snapshot
Event Time:
ATXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXS alerts
High impacting Astria Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXS
News
- Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUNPR Newswire
- Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.MarketBeat
- Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition [Yahoo! Finance]Yahoo! Finance
- Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
ATXS
Earnings
- 11/12/25 - Miss
ATXS
Sec Filings
- 12/3/25 - Form 425
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- ATXS's page on the SEC website